Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
3.395
-0.315 (-8.49%)
Mar 31, 2025, 10:53 AM EDT - Market open
Sagimet Biosciences Employees
Sagimet Biosciences had 14 employees as of December 31, 2024. The number of employees increased by 4 or 40.00% compared to the previous year.
Employees
14
Change (1Y)
4
Growth (1Y)
40.00%
Revenue / Employee
n/a
Profits / Employee
-$3,254,786
Market Cap
109.30M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | 4 | 40.00% |
| Dec 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 10 | 3 | 42.86% |
| Dec 31, 2020 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SGMT News
- 19 days ago - Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 20 days ago - Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - GlobeNewsWire
- 23 days ago - Sagimet Biosciences' Denifanstat Should Be Worth More Today - Seeking Alpha
- 4 months ago - Sagimet: More Than Just A MASH Drug Development Biotech - Seeking Alpha
- 4 months ago - Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne - PRNewsWire
- 5 months ago - Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha
- 6 months ago - Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - GlobeNewsWire
- 6 months ago - Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH - GlobeNewsWire